Drug Profile
Research programme: anti-ganglioside antibody - Arana
Alternative Names: ART150; CEP-37249; DMF10; EGX-150Latest Information Update: 17 Oct 2011
Price :
$50
*
At a glance
- Originator University of Massachusetts Medical School
- Developer Cephalon
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Ganglioside inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lung cancer; Malignant melanoma
Most Recent Events
- 14 Oct 2011 Cephalon has been acquired by Teva Pharmaceutical Industries
- 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
- 16 Mar 2009 Preclinical development is ongoing in USA